Lung adenocarcinoma

This Phase 3 trial tests whether adding the targeted drug calderasib to the immunotherapy pembrolizumab helps people with a specific KRAS G12C-mutated lung cancer live longer without their cancer growing. About 675 participants with advanced non-squamous non-small cell lung cance…

This early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with ca…

This study tests whether taking special gut bacteria capsules (RMT) alongside standard chemotherapy and immunotherapy can help control advanced lung cancer. About 82 people with untreated non-small cell lung cancer will receive either RMT or a placebo. The goal is to see if the b…

This early-phase trial tests SL-28, a cell therapy made from donor immune cells, in 60 people with advanced solid tumors (like lung, pancreatic, or breast cancer) that haven't responded to standard treatments. The study aims to find a safe dose and see if the therapy can shrink t…

This study tests a new drug called TUB-040 for people with ovarian cancer that no longer responds to platinum chemotherapy, or with a type of lung cancer that has come back. TUB-040 is an antibody-drug conjugate, meaning it delivers a powerful chemotherapy directly to cancer cell…

This study tests a new targeted therapy called MK-1084, alone or combined with other drugs, in 190 people with advanced non-squamous non-small cell lung cancer that has a specific KRAS G12C mutation and has worsened after prior treatments. The main goals are to check safety and s…

This early-phase study tests a new drug called JNJ-87890387 in people with advanced solid tumors that have spread or cannot be removed. The drug is designed to help the immune system attack cancer cells. The main goals are to find a safe dose and to check for side effects. About …

This early-phase study tests an experimental drug called JNJ-89862175 in people with advanced solid tumors (lung, kidney, ovarian, or uterine cancers that have spread). The drug is designed to deliver a toxic payload directly to cancer cells. The main goals are to find a safe dos…

This study tests a new drug called Rina-S in about 240 people with advanced non-small cell lung cancer. The goal is to see if the drug can shrink tumors or slow cancer growth. All participants receive the active drug, and treatment may continue as long as it helps and side effect…

This study tests a new drug called ASP546C in people with advanced stomach, gastroesophageal junction, pancreatic, or certain other solid tumors. The drug is given as an infusion every 3 weeks. The study has two parts: Part 1 finds the best dose in stomach/GEJ cancer patients, an…

This study tests a new drug called AZD5335, alone or with other cancer medicines, in people with advanced solid tumors like ovarian, lung, and endometrial cancers. The goal is to see if the drug is safe, tolerable, and shows signs of shrinking tumors. About 506 participants will …

This early-phase trial is testing an experimental biologic drug, DBC-664, in adults with advanced solid tumors such as ovarian, lung, and stomach cancers that have spread or come back. The study has two parts: first, finding a safe dose, and then expanding to see how well the dru…

This early-stage trial is testing an experimental drug called SIM0505 in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug shrinks tumors. About 414 participants will re…

This study tests an experimental drug, atamparib, in 178 adults with advanced or metastatic non-small cell lung cancer (a common type of lung cancer) that has not responded to standard treatments. The trial has two parts: first, finding the safest dose, then checking how well it …

This study tests a new oral drug called NXP900 in people with advanced solid tumors (like lung, kidney, or mesothelioma) that have not responded to standard treatments. The trial has two parts: first, finding the right dose, and then seeing if the drug shrinks tumors. It is a fir…

This study tests whether adding a short course of a MEK inhibitor (mirdametinib) to standard chemoimmunotherapy is safe and effective for people with advanced non-squamous non-small cell lung cancer that has low PDL1 levels. The trial has two parts: first finding the best dose, t…

This study tests a new drug (firmonertinib) combined with radiation therapy for people with a specific type of stage III lung cancer that cannot be removed by surgery. The cancer must have a rare change in the EGFR gene. The goal is to see if the combination can delay cancer grow…

This study is for people with a specific type of advanced lung cancer (EGFR L858R mutation). It tests a treatment plan that starts with a targeted drug (aumolertinib) alone for 6 weeks, then adds chemotherapy for 4 cycles, and finally continues with the targeted drug alone. The g…

This early-phase study tests a new drug called CT-95 in people with advanced cancers that have a protein called mesothelin on their cells. The main goals are to find a safe dose and see if the drug can shrink tumors. About 70 adults with ovarian, lung, pancreatic, or other mesoth…

This study tests a new drug called MORAb-202 that targets a protein (folate receptor alpha) found on some cancer cells. It is for people with ovarian, endometrial, non-small cell lung, or triple-negative breast cancer. The trial has two parts: first to find the safest dose, then …

This study tests whether adding the experimental drug LP-300 to standard chemotherapy can help people who have never smoked and have advanced lung cancer that has returned after targeted therapy. About 90 participants will receive either the drug combo or chemo alone. The goal is…

This study tests whether the drug osimertinib can stop small, hazy spots (called GGNs) in the lungs from growing after surgery for a specific type of lung cancer. About 43 adults with early-stage lung cancer and an EGFR mutation will take a daily pill for one year. The goal is to…

This study tests whether the drug osimertinib can stop or shrink small, hazy lung spots (called ground-glass nodules) that remain after surgery for a type of lung cancer. About 59 adults with EGFR-mutant lung adenocarcinoma will take one pill daily. The goal is to see if the drug…

This early-stage trial tests MGC028, a drug that delivers a cancer-killing agent directly to tumor cells. About 124 adults with advanced lung, bile duct, pancreatic, or colorectal cancers that have stopped responding to standard treatments will receive the drug every three weeks.…

This early-stage trial is testing a new drug called TGW101 in people with advanced solid tumors that have not responded to other treatments. TGW101 is given in two parts: an antibody-drug conjugate and a chemical trigger that activates it. The main goal is to check safety and fin…

This study compares two types of surgery for people with small (≤2 cm) lung adenocarcinoma that does not have aggressive features. One surgery removes only the part of the lung with the tumor (segmentectomy), while the other removes the entire lobe (lobectomy). The goal is to see…

This study tests a new drug called TNG456, alone or with another drug (abemaciclib), in people with advanced cancers that have lost a gene called MTAP. The trial has two parts: first finding a safe dose, then testing how well it shrinks tumors. Up to 191 adults with lung cancer, …

This study tests a combination of two targeted drugs (defactinib and avutometinib) plus an immunotherapy (nivolumab) in people with a specific type of advanced lung cancer (LKB1-mutant adenocarcinoma) that has stopped responding to standard treatment. The goal is to see if this t…

This phase 3 trial tests two ways to treat lung cancer that has spread to the brain. One group gets targeted radiation to each tumor plus a drug (bevacizumab) that starves tumors of blood. The other group gets whole-brain radiation that tries to avoid the memory centers. The stud…

This early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack cancer, and give them back after a short course of chemotherapy. T…

This study tests a new treatment for people with advanced lung cancer that cannot be removed by surgery. It combines a special type of radiation that targets only the center of the tumor with an immunotherapy drug that was used before. The goal is to see if this combination can s…

This study tests whether a diabetes drug called dapagliflozin is safe to give before surgery in people with early-stage lung adenocarcinoma. About 48 participants will take the drug for a short time before their planned surgery. The goal is to see if the drug can help make surger…

This study tests whether freezing a tumor (cryoablation) plus standard immunotherapy and chemotherapy helps people with advanced lung cancer live longer. About 214 participants will be randomly assigned to receive either the standard drug combination alone or with the freezing tr…

This study is for people with a specific type of advanced lung cancer (ALK-positive) that has gotten worse during or after treatment with the drug lorlatinib. Researchers want to see if a different drug, iruplinalkib, can help control the cancer for a longer time. About 20 adults…

This study tests a new drug called TST001, an antibody that targets a protein called Claudin18.2 found on some cancer cells. It is given alone or with chemotherapy to people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check s…

This study tests whether adding the drug bevacizumab to a precise type of radiation therapy (fractionated stereotactic radiotherapy) can better control multiple brain tumors that have spread from lung adenocarcinoma. About 258 adults with 1 to 20 brain metastases will take part. …

This trial tests an experimental imaging agent called [68Ga]Ga-DWJ155 in adults with advanced cancers of the breast, lung, or stomach. The agent is designed to attach to tumor cells and show up on PET scans, helping doctors see where cancer has spread. Researchers will measure ho…

This early-phase study tests a new radioactive imaging agent called [68Ga]Ga-DWJ155 in 36 adults with advanced breast cancer or non-small cell lung cancer. The agent is designed to bind to a target on cancer cells and show up on PET scans, helping doctors see where the cancer has…

This study explores whether a common blood test that measures how well blood clots (called TEG) can also act as a biomarker for cancer. Researchers will compare TEG results from patients with several types of cancer (liver, pancreas, bile duct, esophagus, colorectal, and lung) ag…

This study tests a new radioactive imaging agent that targets a protein called MSLN, found on some cancer cells. Researchers will use PET scans to see if this agent can better detect and stage ovarian cancer, lung adenocarcinoma, and pancreatic cancer in 100 patients and healthy …

This study is testing whether certain biomarkers in blood and lung tissue can help doctors tell if a lung nodule is cancer, predict the risk of cancer coming back after surgery, and monitor for late recurrence. Researchers will follow 250 people with suspicious lung nodules or re…

This study is testing whether eating a low-glucose, high-fat (ketogenic) diet for 7 days before a PET scan can make the scan better at finding a specific type of slow-growing lung cancer called lepidic-predominant adenocarcinoma. This cancer often doesn't show up well on standard…

This study is looking for new biological markers in the fluid that builds up around the lungs (pleural effusion) in people with lung adenocarcinoma. Researchers will compare these markers between cancerous and non-cancerous fluid samples from 100 patients. The goal is to see if t…

This study is testing two new diagnostic kits that use blood samples or tumor tissue to predict if early-stage lung cancer will come back after surgery. Researchers will enroll 236 people with stage IA to IIIA lung cancer who have had their tumor fully removed. The goal is to see…

This study will test a method that combines microwave ablation (using heat to destroy lung nodules) with a biopsy (taking a tissue sample) to diagnose ground-glass lung cancer. Researchers plan to enroll 200 people with small lung nodules who cannot or choose not to have surgery.…

This study tests a new PET scan tracer called Me-4FDG to see if it can find lung cancer earlier and more accurately. About 60 adults with lung nodules will get the tracer and a PET scan. The goal is to improve early diagnosis and reduce unnecessary procedures.

Researchers are testing whether giving targeted radiation to lung tumors before a lung transplant can create an immune response that helps the body fight cancer. The trial enrolls adults with end-stage lung disease and hard-to-treat lung cancer who need a transplant. The goal is …

This study tests whether yoga and mindfulness programs can improve quality of life, reduce inflammation, and even affect gene activity in people who have survived lung, colon, or non-Hodgkin's lymphoma cancer. One hundred survivors, at least six months past treatment, will be ran…

This study tests whether vortioxetine, an antidepressant known to boost thinking skills, can reduce the mental fogginess caused by the lung cancer drug lorlatinib. About 24 adults with advanced ALK-positive lung cancer who are already taking lorlatinib will receive vortioxetine. …

This study tests whether regular phone support from a trained lay health worker can improve quality of life for veterans with lung cancer. 194 veterans will either receive usual care or weekly calls for 6 months. The goal is to see if this extra support helps with healthcare plan…

This study looks at factors that might increase the risk of lung cancer in women aged 40 to 74 who have never smoked. Researchers will collect questionnaires and blood samples from 500 women—some with lung cancer and some without—to analyze genetic and exposure-related clues. The…

This study looks for biological markers in the blood that could help diagnose and predict the course of three serious lung conditions: COPD, idiopathic pulmonary fibrosis (IPF), and lung cancer. Researchers will analyze blood samples from 120 adults with these diseases to find li…

This study aims to collect health information from 12,000 adults with lung or other chest cancers. Researchers want to understand why some people respond better to treatment than others, even when their cancer stage is the same. By gathering data from routine care, they hope to i…

This study looks at whether testing lung cancer cells in a lab can predict which drugs will work best for each patient. Researchers will collect fluid from around the lungs of 400 people with lung cancer who need drainage for shortness of breath. They will grow the cancer cells i…

This large study in Ohio is looking at whether advanced genomic testing and immunotherapy decision support can help people with stage IV non-small cell lung cancer live longer and have a better quality of life. Researchers will compare standard care with a more personalized appro…

This study aims to create a decision aid for people with lung adenocarcinoma who need to decide whether to have molecular testing after surgery. Researchers will interview patients, family members, and doctors to understand what information is needed. The final tool will be teste…

This study aims to find how often inherited gene changes occur in Mexican patients with a type of lung cancer called adenocarcinoma. Researchers will collect blood samples from 332 participants to look for these gene changes and see if they affect survival or treatment options. T…